Adam Boehler

Adam Boehler, briefly a college roommate of President Donald Trump’s son-in-law and adviser Jared Kushner, ran the International Development Finance Corporation starting in fall 2019. The DFC had been created with bipartisan support in 2018 to help steer private investment to government-funded projects in the developing world. Boehler left the DFC on Jan. 20 2021, the day of President Joe Biden’s inauguration, and was succeeded by Dev Jagadesan, now acting CEO. Boehler was been CMS Innovation Center director for about a year and since then has led the launch of several value-based payment models including a direct contracting option. Prior to joining HHS, Boehler was the founder of home healthcare company Landmark Health, which assumed risk for its more than 80,000 patients, many of whom are chronically ill or elderly. He also founded Avalon Healthcare Solutions, a laboratory benefit services company. Trump selected Boehler to be CEO of the U.S. International Development Finance Corp., an agency recently formed under the Trump administration and charged with overseeing finances of projects in foreign countries.The U.S. International Development Finance Corp. was formed in 2018 through the combination of two agencies: the Overseas Private Investment Corp. and the Development Credit Authority. In 2021, auditors found DFC has not tracked how much money it spent on the Covid supply-chain program but agency officials said at least $1 million was spent sifting through the proposals. In July 2020 the agency announced a $765 million commitment to work with Kodak to make generic drug ingredients needed in the pandemic. Kodak’s stocks soared by 570 percent and the company said it was planning to expand existing facilities in Rochester, New York, and St. Paul, Minnesota. The deal came under immediate scrutiny and never went through. The loan that is the furthest along in the process is an application from a Connecticut-based company called ApiJect, but the GAO says the project to build a new facility creating 650 jobs to make prefilled injectors for Covid vaccines has been delayed because the company has “encountered delays securing the necessary property rights for the project site.”